2021
Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease‐19
Khera R, Clark C, Lu Y, Guo Y, Ren S, Truax B, Spatz ES, Murugiah K, Lin Z, Omer SB, Vojta D, Krumholz HM. Association of Angiotensin‐Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease‐19. Journal Of The American Heart Association 2021, 10: e018086. PMID: 33624516, PMCID: PMC8403305, DOI: 10.1161/jaha.120.018086.Peer-Reviewed Original ResearchConceptsAngiotensin receptor blockersLower hospitalization riskACE inhibitorsCOVID-19 hospitalizationHospitalization riskHospital mortalityReceptor blockersValidation cohortAcute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionEnzyme inhibitorsSyndrome coronavirus 2 infectionAngiotensin converting enzyme (ACE) inhibitorsCoronavirus 2 infectionRisk of hospitalizationCoronavirus disease-19SARS-CoV-2COVID-19 preventionHypertensive patientsInpatient cohortOutpatient cohortContemporary cohortStudy cohortOutpatient studyMedicare group
2018
Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering
Wang S, Khera R, Das SR, Vigen R, Wang T, Luo X, Lu R, Zhan X, Xiao G, Vongpatanasin W, Xie Y. Usefulness of a Simple Algorithm to Identify Hypertensive Patients Who Benefit from Intensive Blood Pressure Lowering. The American Journal Of Cardiology 2018, 122: 248-254. PMID: 29880288, DOI: 10.1016/j.amjcard.2018.03.361.Peer-Reviewed Original ResearchConceptsSystolic Blood Pressure Intervention TrialIntensive BP loweringUrinary albumin-creatinine ratioFavorable risk-benefit profileAlbumin-creatinine ratioBP loweringRisk-benefit profileHypertensive patientsBlood pressureMajor adverse cardiovascular event ratesAdverse cardiovascular event ratesIntensive blood pressure loweringMajor adverse cardiovascular eventsRemaining low-risk patientsSimple risk prediction modelIntensive blood pressureStandard BP loweringAdverse cardiovascular eventsBlood pressure loweringSerious adverse eventsCardiovascular event ratesLarge randomized trialsLow-risk patientsSubset of patientsCardiovascular disease risk